Studies utilising humanised NSCLC CDX/PDX models have demonstrated the ability of anti-PD1 and anti-PDL1 to slow tumour growth in vivo123,124 (Table 3), presenting new opportunities for combination trials. Here, PDCD1 is linked to neoplasm.